Oops...

Slider with alias "healthy innovation event" not found.

The 2016 Universal Access and Affordable Medicines Forum of the European Public Health Alliance.

Organised under the auspices of the Polish Permanent Representation to the EU.

Speakers

Sessions

Attendees

Health is a fundamental universal right which relies on fair and equal access to medicines. Nevertheless, it appears that patients across Europe may suffer from lack of affordability of many life-saving medicines.

The programme will discuss the current situation of access to medicines in Europe, EU regulatory developments and explore policy recommendations for affordable medicines that serve public health needs and promote genuine innovation for all.

Join the discussion on Twitter using #HealthyInnovation!

Relive the event

AGENDA

STORIFY

Speakers and Moderators

Dr Deborah Cohen

Associate Editor, British Medical Journal (BMJ)

Moderator

Sabine Vogler

Head, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies

Juan José Rodríguez Sendín

President, General Medical Council of Spain (CGCOM)

Beata Stepniewska

Deputy Director-General & Head of Regulatory Affairs, Medicines For Europe

Mark Davis

Director, Government affairs & Policy – EMEA, Gilead

Jürgen Windeler

Director, IQWiG

Gregg Gonsalves

Co-Director, Global Health Justice Partnership, Yale University & patient activist

Courtney Davis

Senior Lecturer, Department of Social Science, Health and Medicine, King’s College London,
London, UK

Wolf-Dieter Ludwig

Chairman, Drug Commission, German Medical Association – Member, Management Board, European Medicines Agency (EMA)

Alexander Natz

Secretary General, European Confederation of Pharmaceutical Enterpreneurs (EUCOPE)

Eric Stobbaerts

International Development Advisor, Drugs for Neglected Diseases Initiative (DNDi)

Irina Cleemput

Senior Health Economist, Belgian Health Care Knowledge Centre (KCE)

Denis Lacombe

Director-General, European Organisation for Research and Treatment of Cancer (EORTC)

Boris Azais

Director Public Policy for Europe and Canada, MSD

Silvio Garattini

Director, Mario Negri Institute for Pharmacological Research

Flora Giorgio

Head of Sector Health Technology Assessment, Unit Medicinal Products (B4), DG SANTE, European Commission

Elizabeth Kuiper

Director European Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Marc Van de Casteele

Coordinator of pharmaceutical assessment, Belgian Institute for Health Insurance and Invalidity (RIZIV/INAMI)

Katy Athersuch

Medical Innovation & Access Policy Adviser, Médecins Sans Frontières-Access Campaign

From Twitter

<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">Our citizens should not pay twice for their medicines <a href="https://twitter.com/hashtag/healthyinnovation?src=hash">#healthyinnovation</a> <a href="https://t.co/HBdAzuVi9f">pic.twitter.com/HBdAzuVi9f</a></p>— Catta (@CattaFra) <a href="https://twitter.com/CattaFra/status/803521025619140608">November 29, 2016</a></blockquote> <script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>

<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">.<a href="https://twitter.com/gregggonsalves">@gregggonsalves</a> describes adaptive pathways as a typical example of regulatory capture by the pharma industry <a href="https://twitter.com/hashtag/HealthyInnovation?src=hash">#HealthyInnovation</a></p>— EPHA (@EPHA_EU) <a href="https://twitter.com/EPHA_EU/status/803561487142973440">November 29, 2016</a></blockquote> <script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>

<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">Our industry wants to be part of the solution in making medicines more accessible and healthcare more sustainable <a href="https://twitter.com/hashtag/healthyinnovation?src=hash">#healthyinnovation</a> <a href="https://twitter.com/EFPIA">@EFPIA</a></p>— Elizabeth Kuiper (@kuiper_em) <a href="https://twitter.com/kuiper_em/status/803529678971604993">November 29, 2016</a></blockquote> <script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>

<blockquote class="twitter-tweet" data-lang="en"><p lang="en" dir="ltr">Garattini: Legislation must be revised to require added therapeutic value for new medicines <a href="https://twitter.com/hashtag/HealthyInnovation?src=hash">#HealthyInnovation</a> <a href="https://t.co/BdgIu59OX3">pic.twitter.com/BdgIu59OX3</a></p>— EPHA (@EPHA_EU) <a href="https://twitter.com/EPHA_EU/status/803612635568607233">November 29, 2016</a></blockquote> <script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>

FIND #HEALTHYINNOVATION ON STORIFY

Organisers

Yannis Natsis

Policy Manager for Universal Access and Affordable Medicines

Lilianna Michalik

Health Counsellor at Permanent Representation of Poland to the EU